AAPL   383.68 (+0.25%)
MSFT   213.67 (-0.30%)
FB   245.07 (+0.23%)
GOOGL   1,539.01 (+1.34%)
AMZN   3,200.00 (+0.55%)
NVDA   419.17 (-0.28%)
CGC   17.42 (+8.74%)
MU   50.70 (+1.44%)
GE   6.69 (+1.67%)
TSLA   1,544.65 (+10.78%)
AMD   55.88 (-2.41%)
T   30.13 (+2.00%)
ACB   12.02 (+2.12%)
F   6.10 (+4.27%)
GILD   76.32 (+2.15%)
DIS   119.34 (+2.16%)
BAC   24.02 (+5.49%)
NFLX   548.73 (+8.07%)
BA   178.44 (+2.98%)
AAPL   383.68 (+0.25%)
MSFT   213.67 (-0.30%)
FB   245.07 (+0.23%)
GOOGL   1,539.01 (+1.34%)
AMZN   3,200.00 (+0.55%)
NVDA   419.17 (-0.28%)
CGC   17.42 (+8.74%)
MU   50.70 (+1.44%)
GE   6.69 (+1.67%)
TSLA   1,544.65 (+10.78%)
AMD   55.88 (-2.41%)
T   30.13 (+2.00%)
ACB   12.02 (+2.12%)
F   6.10 (+4.27%)
GILD   76.32 (+2.15%)
DIS   119.34 (+2.16%)
BAC   24.02 (+5.49%)
NFLX   548.73 (+8.07%)
BA   178.44 (+2.98%)
AAPL   383.68 (+0.25%)
MSFT   213.67 (-0.30%)
FB   245.07 (+0.23%)
GOOGL   1,539.01 (+1.34%)
AMZN   3,200.00 (+0.55%)
NVDA   419.17 (-0.28%)
CGC   17.42 (+8.74%)
MU   50.70 (+1.44%)
GE   6.69 (+1.67%)
TSLA   1,544.65 (+10.78%)
AMD   55.88 (-2.41%)
T   30.13 (+2.00%)
ACB   12.02 (+2.12%)
F   6.10 (+4.27%)
GILD   76.32 (+2.15%)
DIS   119.34 (+2.16%)
BAC   24.02 (+5.49%)
NFLX   548.73 (+8.07%)
BA   178.44 (+2.98%)
AAPL   383.68 (+0.25%)
MSFT   213.67 (-0.30%)
FB   245.07 (+0.23%)
GOOGL   1,539.01 (+1.34%)
AMZN   3,200.00 (+0.55%)
NVDA   419.17 (-0.28%)
CGC   17.42 (+8.74%)
MU   50.70 (+1.44%)
GE   6.69 (+1.67%)
TSLA   1,544.65 (+10.78%)
AMD   55.88 (-2.41%)
T   30.13 (+2.00%)
ACB   12.02 (+2.12%)
F   6.10 (+4.27%)
GILD   76.32 (+2.15%)
DIS   119.34 (+2.16%)
BAC   24.02 (+5.49%)
NFLX   548.73 (+8.07%)
BA   178.44 (+2.98%)
Log in

NASDAQ:ARDSAridis Pharmaceuticals Stock Price, Forecast & News

$6.41
+0.01 (+0.16 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$6.10
Now: $6.41
$6.74
50-Day Range
$6.06
MA: $6.91
$8.51
52-Week Range
$3.80
Now: $6.41
$12.40
Volume18,000 shs
Average Volume10,483 shs
Market Capitalization$57.20 million
P/E RatioN/A
Dividend YieldN/A
Beta0.03
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb that is in Phase IIa trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 to treat infections caused by A. baumannii; AR-201, an anti- respiratory syncytial virus F-protein mAb; and AR-501, an anti-infective therapy to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in San Jose, California.
Read More
Aridis Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.29 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARDS
CUSIPN/A
CIKN/A
Phone408-385-1742

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.02 million
Book Value$0.41 per share

Profitability

Net Income$-29,680,000.00

Miscellaneous

Employees25
Market Cap$57.20 million
Next Earnings Date8/10/2020 (Estimated)
OptionableNot Optionable

Receive ARDS News and Ratings via Email

Sign-up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter.

Aridis Pharmaceuticals (NASDAQ:ARDS) Frequently Asked Questions

How has Aridis Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Aridis Pharmaceuticals' stock was trading at $6.46 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ARDS stock has decreased by 0.8% and is now trading at $6.41. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Aridis Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aridis Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aridis Pharmaceuticals.

When is Aridis Pharmaceuticals' next earnings date?

Aridis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Aridis Pharmaceuticals.

How were Aridis Pharmaceuticals' earnings last quarter?

Aridis Pharmaceuticals Inc (NASDAQ:ARDS) announced its quarterly earnings results on Tuesday, May, 12th. The company reported ($0.73) EPS for the quarter, missing the Zacks' consensus estimate of ($0.67) by $0.06. View Aridis Pharmaceuticals' earnings history.

What price target have analysts set for ARDS?

5 Wall Street analysts have issued 1-year target prices for Aridis Pharmaceuticals' shares. Their forecasts range from $11.00 to $22.00. On average, they anticipate Aridis Pharmaceuticals' stock price to reach $16.60 in the next year. This suggests a possible upside of 159.0% from the stock's current price. View analysts' price targets for Aridis Pharmaceuticals.

Has Aridis Pharmaceuticals been receiving favorable news coverage?

News coverage about ARDS stock has trended negative on Friday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aridis Pharmaceuticals earned a media sentiment score of -2.4 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news about Aridis Pharmaceuticals.

Are investors shorting Aridis Pharmaceuticals?

Aridis Pharmaceuticals saw a decline in short interest in the month of June. As of June 30th, there was short interest totaling 25,800 shares, a decline of 7.2% from the June 15th total of 27,800 shares. Based on an average daily volume of 7,300 shares, the short-interest ratio is presently 3.5 days. Approximately 0.5% of the company's stock are sold short. View Aridis Pharmaceuticals' Current Options Chain.

Who are some of Aridis Pharmaceuticals' key competitors?

What other stocks do shareholders of Aridis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aridis Pharmaceuticals investors own include Juno Therapeutics (JUNO), Gilead Sciences (GILD), VBI Vaccines (VBIV), Cidara Therapeutics (CDTX), Inovio Pharmaceuticals (INO), Sanofi (SNY), Dynavax Technologies (DVAX), Marina Biotech (MRNA), Matinas BioPharma (MTNB) and Ocular Therapeutix (OCUL).

Who are Aridis Pharmaceuticals' key executives?

Aridis Pharmaceuticals' management team includes the following people:
  • Dr. Eric J. Patzer, Exec. Chairman (Age 71, Pay $233.12k)
  • Dr. Vu L. Truong, Founder, CEO & Director (Age 56, Pay $652.5k)
  • Mr. Fred Kurland, Consultant (Age 69, Pay $226.19k)
  • Mr. Michael A. Nazak, Chief Financial Officer (Age 61)
  • Mr. Jeffrey J. Fessler Esq., J.D., Acting Gen. Counsel (Age 57)

When did Aridis Pharmaceuticals IPO?

(ARDS) raised $28 million in an initial public offering on Tuesday, August 14th 2018. The company issued 2,000,000 shares at a price of $13.00-$15.00 per share. Cantor acted as the underwriter for the IPO and Maxim Group and Northland Capital Markets were co-managers.

What is Aridis Pharmaceuticals' stock symbol?

Aridis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARDS."

How do I buy shares of Aridis Pharmaceuticals?

Shares of ARDS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aridis Pharmaceuticals' stock price today?

One share of ARDS stock can currently be purchased for approximately $6.41.

How big of a company is Aridis Pharmaceuticals?

Aridis Pharmaceuticals has a market capitalization of $57.20 million and generates $1.02 million in revenue each year. The company earns $-29,680,000.00 in net income (profit) each year or ($3.51) on an earnings per share basis. Aridis Pharmaceuticals employs 25 workers across the globe.

What is Aridis Pharmaceuticals' official website?

The official website for Aridis Pharmaceuticals is www.aridispharma.com.

How can I contact Aridis Pharmaceuticals?

Aridis Pharmaceuticals' mailing address is 5941 Optical Ct, San Jose CA, 95138. The company can be reached via phone at 408-385-1742 or via email at [email protected]

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.